Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC€™s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.

You may also be interested in...



Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care

Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.

Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care

Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.

Hectorol Label Hectored by ISMP

Medical safety organization says FDA will "look into" labeling of Bone Care International's Hectorol, which includes a mu and trailing zero.

Related Content

Topics

UsernamePublicRestriction

Register

PS060435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel